Nanogen and Epoch Biosciences Adjourn Special Stockholder Meetings Until December 15, 2004 to Vote on Merger

    SAN DIEGO and BOTHELL, Wash., Dec. 8 /PRNewswire-FirstCall/ -- Nanogen,
 Inc. (Nasdaq:   NGEN) and Epoch Biosciences, Inc. (Nasdaq:   EBIO), announced
 today that each company adjourned its special meeting of stockholders that
 took place today in order for Nanogen to obtain the votes necessary to reach a
 quorum.  The Nanogen special meeting was adjourned and the vote postponed
 until December 15, 2004 at 2:00 p.m. Pacific time at its offices at 10398
 Pacific Center Court, San Diego, California.  The Epoch special meeting was
 adjourned and the vote postponed until December 15, 2004 at 2:00 p.m. Pacific
 time at its offices at 21720 23rd Drive SE, Bothell, Washington.
     The Nanogen special meeting was adjourned because an insufficient number
 of stockholders were present or represented by proxy in order to establish a
 quorum.  The holders of a majority of the issued and outstanding Nanogen
 common stock entitled to vote, present in person or represented by proxy,
 constitutes a quorum for transaction of business at the special meeting.  As
 of the commencement of its special meeting, Nanogen has received proxies
 representing approximately 16.4 million of the required 16.7 million share
 votes needed to establish a quorum.  Over 90% of the proxies received have
 been in favor of the proposals on Nanogen's proxy statement for the special
 meeting.  Proposal 1 would approve the issuance of Nanogen stock to complete
 the merger with Epoch.  Proposal 2 would amend Nanogen's certificate of
 incorporation to increase the number of authorized shares of Nanogen common
 stock.  Valid proxies submitted by Nanogen stockholders prior to the
 December 8, 2004 meeting will continue to be valid for purposes of the
 December 15, 2004 reconvened meeting.
     Nanogen stockholders as of October 26, 2004 who have not voted and wish to
 do so should contact the company's proxy solicitor, Georgeson Shareholder at
 (800) 459-3121.
     In response to the adjournment of the Nanogen special meeting, Epoch
 adjourned its special meeting prior to voting on the proposal to adopt the
 merger agreement with Nanogen and approve the merger.  Epoch had established a
 quorum at its meeting and it had sufficient votes to approve the proposal to
 adopt the merger agreement and to approve the merger.  Valid proxies submitted
 by Epoch stockholders prior to the December 8, 2004 meeting will continue to
 be valid for purposes of the December 15, 2004 reconvened meeting.
     Epoch stockholders as of October 26, 2004 who have not voted and wish to
 do so should contact the company's proxy solicitor, MacKenzie Partners at
 (800) 322-2885 or proxy@mackenziepartners.com.
 
     About Nanogen, Inc. (Pre-Merger)
     Nanogen's advanced diagnostics provide physicians and patients worldwide
 with sophisticated information to predict, diagnose and treat disease.
 Research and clinical reference labs use the highly accurate and reliable
 NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarrays
 and analyte specific reagents to develop tests to detect mutations associated
 with genetic diseases.  The next generation instrument system, the NanoChip(R)
 400, is expected to be available in 2005.  Nanogen's subsidiary SynX offers a
 line of point-of-care diagnostic tests and is building expertise in cardiac
 related health conditions.  Nanogen's ten years of pioneering research
 involving nanotechnology may also have future applications in medical
 diagnostics, biowarfare and other industries.  For additional information
 please visit Nanogen's website at www.nanogen.com.
 
     About Epoch Biosciences, Inc. (Pre-Merger)
     Epoch Biosciences, Inc. develops and sells proprietary products with
 commercial applications in the genomics and molecular diagnostics fields.
 Epoch's technology has numerous applications including the detection of
 inherited diseases, single nucleotide polymorphisms (SNPs) to identify
 individuals at risk for disease or adverse drug reactions, and gene expression
 measurement.  The company's chemical reagents enhance the performance of
 genetic analysis procedures, and are compatible with the majority of DNA
 analysis systems currently employed or under development for research and
 diagnostic use.  The company has an established presence in the research
 market through licenses to leading genomics companies, global distribution
 agreements and direct sales to end-users.  Epoch also participates in the
 industrial/bioterrorism sectors and has entered the diagnostics market.
 Information about Epoch is available at www.epochbio.com.
 
     Forward-Looking Statement
     This press release contains forward-looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward-looking statements, including statements
 about the outcome of the special meetings of Nanogen and Epoch, consummation
 of the pending merger of Nanogen and Epoch, future financial and operating
 results of the combined company and benefits of the pending merger, whether
 patents owned or licensed by Nanogen will be developed into products, whether
 the patents owned by Nanogen offer any protection against competitors with
 competing technologies, whether products under development can be successfully
 developed and commercialized, whether results reported by our customers or
 partners can be identically replicated, and other risks and uncertainties
 discussed under the caption "Factors That May Affect Results" and elsewhere in
 Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
 Exchange Commission.  These forward-looking statements speak only as of the
 date hereof.  Nanogen disclaims any intent or obligation to update these
 forward-looking statements.
     In addition to the specific risks identified in the preceding paragraph,
 mergers involve a number of special risks, including diversion of management's
 attention to the assimilation of the technology and personnel of acquired
 businesses, costs related to the merger and the integration of acquired
 products, technologies and employees into Nanogen's business and product
 offerings.  Achieving the anticipated benefits of the pending merger will
 depend, in part, upon whether the integration of the acquired products,
 technology, or employees is accomplished in an efficient and effective manner,
 and there can be no assurance that this will occur.  The difficulties of such
 integration may be increased by the necessity of coordinating geographically
 disparate organizations, the complexity of the technologies being integrated,
 and the necessity of integrating personnel with disparate business backgrounds
 and combining different corporate cultures.  The inability of management to
 successfully integrate the business of the two companies, and any related
 diversion of management's attention, could have a material adverse effect on
 the combined company's business, operating results and financial condition.
     The proxies held by Nanogen and Epoch for their respective special
 meetings are revocable by the granting stockholders at any time prior to
 voting at the special meetings.  Revocations of proxies by Nanogen or Epoch
 stockholders could materially impact the ability of Nanogen to establish a
 quorum and obtain approval of its proposals and the ability of Epoch to obtain
 approval of its proposal.
 
     Additional Information about the Merger and Where to Find It
     In connection with the merger of Nanogen and Epoch, Nanogen has filed a
 registration statement on Form S-4, as amended on October 26, 2004, which
 includes a prospectus of Nanogen and a joint proxy statement for each of
 Nanogen's and Epoch's special stockholder meetings, with the Securities and
 Exchange Commission.  Investors and security holders are advised to read the
 registration statement, prospectus and joint proxy statement because they
 contain important information about the proposed merger.  Investors and
 security holders may obtain a free copy of the registration statement,
 prospectus and joint proxy statement and other documents filed by Nanogen and
 Epoch with the Securities and Exchange Commission at the Securities and
 Exchange Commission's web site at http://www.sec.gov.  Free copies of the
 registration statement, prospectus and joint proxy statement and other
 documents filed by Nanogen with the Securities and Exchange Commission may
 also be obtained from Nanogen by directing a request to Nanogen, Attention:
 Larry Respess, Secretary, 858-410-4600.  Free copies of the joint proxy
 statement and other documents filed by Epoch with the Securities and Exchange
 Commission may also be obtained from Epoch by directing a request to Epoch,
 Attention: Bert Hogue, Chief Financial Officer, 425-482-5555.
 
 

SOURCE Nanogen, Inc.; Epoch Biosciences, Inc.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.